Biomedical Engineering Reference
In-Depth Information
37. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T,
Mitsuya H, et al. (1989) Designing CD4 immunoadhesins for
AIDS therapy. Nature 337, 525-531.
38. Byrn RA, Mordenti J, Lucas C, Smith D, Marsters SA,
Johnson JS, et al. (1990) Biological properties of a CD4
immunoadhesin. Nature 344, 667-670.
39. ChamowSM,DuliegeAM,AmmannA,KahnJO,AllenJD,
Eichberg JW, et al. (1992) CD4 immunoadhesins in anti-
HIV therapy: new developments. Int. J. Cancer Suppl. 7,
69-72.
40. Ashkenazi A, Capon DJ, Ward RH. (1993) Immunoadhesins.
Int. Rev. Immunol. 10, 219-227.
41. Low SC, Nunes SL, Bitonti AJ, Dumont JA. (2005) Oral
and pulmonary delivery of FSH-Fc fusion proteins via
neonatal Fc receptor-mediated transcytosis. Hum. Reprod.
20, 1805-1813.
42. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE,
Palombella VJ, et al. (2004) Pulmonary delivery of an
erythropoietin Fc fusion protein in non-human primates
through an immunoglobulin transport pathway. Proc. Natl.
Acad. Sci. USA 101, 9763-9768.
43. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ,
Kavanaugh A, et al. (2008) Efficacy and safety of rilonacept
(interleukin-1 Trap) in patients with cryopyrin-associated
periodic syndromes: results from two sequential placebo-
controlled studies. Arthritis Rheum. 58, 2443-2452.
44. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. (2004)
Suppression of angiogenesis and tumor growth by selective
inhibition of angiopoietin-2. Cancer Cell 6, 507-516.
45. Karlan BY, Oza AM, Hansen VL, Richardson GE, Pro-
vencher DM, Ghatage P, et al. (2010) Randomized, double-
blind, placebo-controlled phase II study of AMG 386
combined with weekly paclitaxel in patients (pts) with
recurrent ovarian carcinoma [Abstract 5000]. J. Clin.
Oncol. 28.
46. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silver-
man JM, et al. (2009) Safety, pharmacokinetics, and anti-
tumor activity of AMG 386, a selective angiopoietin inhibitor,
in adult patients with advanced solid tumors. J. Clin. Oncol.
27, 3557-3565.
47. UmpierrezGE,BlevinsT,RosenstockJ,ChengC,AndersonJH,
Bastyr EJ, 3rd. (2011) The effects of LY2189265, a long-acting
glucagon-like peptide-1 analog, in a randomized, placebo-con-
trolled, double-blind study of overweight/obese patients
with type 2 diabetes: the EGO study. Diabetes Obes. Metab.13,
418-425.
48. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F,
et al. (2002) P-selectin glycoprotein ligand-1 (rPSGL-Ig)-
mediated blockade of CD62 selectin molecules protects rat
steatotic liver grafts from ischemia/reperfusion injury. Am. J.
Transplant. 2, 600-608.
49. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R,
Underwood KW, et al. (2009) Single-dose, randomized,
double-blind, placebo-controlled study of ACE-011
(ActRIIA-IgG1) in postmenopausal women. J. Bone Miner.
Res. 24, 744-752.
50. Lachey JL, Wachtman LM, Mansfield KG, Persall RS, Lane
JH, Seehra JS. (2008) Treatment with a soluble activin
receptor type IIb results increased muscle mass in marmosets
[Abstract]. New Dir. Biol. Dis. Skelet. Muscle.
51. Long L, Brennan T, Zanghi J, Palencia S, Cheung R, Aguirre
M, et al. (2009) Preclinical antitumor efficacy of FP-1039, a
soluble FGF receptor 1:Fc conjugate, as a single agent or in
combination with anti-cancer drugs [Abstract]. AACR 100th
Annual Meeting.
52. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Mono-
meric Fc fusions: impact on pharmacokinetic and biological
activity of protein therapeutics. BioDrugs 20, 151-160.
53. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV,
Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols
TC, et al.: Prolonged activity of factor IX as a monomeric Fc
fusion protein. Blood 2010, 115, 2057-2064.
54. Jazayeri JA, Carroll GJ. (2008) Fc-based cytokines: prospects
for engineering superior therapeutics. BioDrugs 22, 11-26.
55. Ashkenazi A, Chamow SM. (1997) Immunoadhesins as
research tools and therapeutic agents. Curr. Opin. Immunol.
9, 195-200.
56. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Strem-
ler KE, Fung VP, et al. (1993) Soluble tumor necrosis
factor (TNF) receptors are effective therapeutic agents in
lethal endotoxemia and function simultaneously as
both TNF carriers and TNF antagonists. J. Immunol. 151,
1548-1561.
57. Ducharme E, Weinberg JM. (2008) Etanercept. Expert Opin.
Biol. Ther. 8, 491-502.
58. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa
MD, et al. (1993) Specific interaction of lymphocyte func-
tion-associated antigen 3 with CD2 can inhibit T cell
responses. J. Exp. Med. 178, 211-222.
59. Burton DR, Woof JM. (1992) Human antibody effector
function. Adv. Immunol. 51, 1-84.
60. Tao MH, Smith RI, Morrison SL. (1993) Structural features of
human immunoglobulin G that determine isotype-specific
differences in complement activation. J. Exp. Med. 178,
661-667.
61. Strohl WR. Non-immunostimulatory antibody and compo-
sitions
containing the
same. US patent
application
2007/0148167 A1, 2007.
62. De Groot AS, Scott DW. (2007) Immunogenicity of protein
therapeutics. Trends Immunol. 28, 482-490.
63. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. (2003)
Rational design and engineering of therapeutic proteins. Drug
Discov. Today 8, 212-221.
64. Emamaullee J, Toso C, Merani S, Shapiro AM. (2009)
Costimulatory blockade with belatacept in clinical and exper-
imental transplantation - a review. Expert Opin. Biol. Ther. 9,
789-796.
65. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N,
Strobertm E, et al. (2005) Rational development of LEA29Y
(belatacept), a high-affinity variant of CTLA4-Ig with
potent immunosuppressive properties. Am. J. Transplant.
5, 443-453.
Search WWH ::
Custom Search